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Application of RNAi-induced gene
expression profiles for prognostic
prediction in breast cancer
Yue Wang1,2, Kenneth M. K. Mark2, Matthew H. Ung2, Arminja Kettenbach3,4, Todd Miller2,3, Wei Xu1,
Wenqing Cheng1, Tian Xia1* and Chao Cheng2,3,5*
Abstract
Homologous recombination (HR) is the primary pathway for repairing double-strand DNA breaks implicating in the
development of cancer. RNAi-based knockdowns of BRCA1 and RAD51 in this pathway have been performed to
investigate the resulting transcriptomic profiles. Here we propose a computational framework to utilize these
profiles to calculate a score, named RNA-Interference derived Proliferation Score (RIPS), which reflects cell
proliferation ability in individual breast tumors. RIPS is predictive of breast cancer classes, prognosis, genome
instability, and neoadjuvant chemosensitivity. This framework directly translates the readout of knockdown
experiments into potential clinical applications and generates a robust biomarker in breast cancer.
Keywords: Homologous recombination pathway, Gene knockdown profiles, Cell proliferation, Cancer prognosis,
Neoadjuvant chemotherapy, Genomic instability
Background
Homologous recombination (HR) is the primary path-
way for repairing double-strand DNA breaks (DSBs)
and is highly conserved in eukaryotic organisms [1, 2].
BRCA1 and BRCA2, the most well-studied genes in this
pathway [3, 4], participate in DNA repair either as es-
sential proteins themselves or regulate other proteins in
the HR pathway to facilitate repair of damaged DNA or
apoptosis if DNA cannot be repaired [5]. BRCA1 and
BRCA2 interact with RAD51 to form complexes that
initiate and facilitate homologous recombination [6–9].
RAD51 catalyzes the key reactions in the HR pathway, in-
cluding homology search and DNA strand invasion [1].
Mutation or deregulation of genes in the HR pathway
has been implicated in the development of many cancer
subtypes including breast cancer [10]. For example,
mutations in BRCA1 and BRCA2 have long been
known to confer cancer susceptibility [11] and women
with a germ-line heterozygous mutation have an overall
increased lifetime risk of developing breast and ovarian
cancers [12, 13]. Although the majority of breast tu-
mors are sporadic and do not carry germline mutations
in BRCA1 or BRCA2 [14], it has been shown that the
HR DNA repair pathway is frequently disrupted by nu-
merous mechanisms [13, 15]. For example, methylation
of the BRCA1 promoter has been shown to transcrip-
tionally silence BRCA1 [16] leading to lower levels of
BRCA1 messenger RNA (mRNA), which correlates with
disease characteristics of breast and ovarian cancers
[17]. When functional BRCA1 or BRCA2 are absent or
dysfunctional and unable to perform HR-mediated repair
of double-strand DNA breaks, alternative error-prone
pathways, such as non-homologous end joining and
single-strand annealing are induced, leading to a signifi-
cant increase in genome instability [18]. In addition, many
drugs have recently been developed to exploit the role of
the HR pathway in cancer development [10] and HR path-
way activity has been implicated in cancer treatment and
drug resistance [10, 19].
Recently, the concept of “BRCAness” has been intro-
duced to investigate sporadic breast cancers with defects
in the HR-mediated DNA repair pathway, which endow
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them with critical features also observed in hereditary
breast cancers carrying BRCA1 or BRCA2 germline
mutation [13, 20]. Genomic features have been selected
to infer BRCAness by comparing BRCA1/2 mutant
samples with hereditary breast tumor samples [21–26].
An alternative strategy is to investigate genes that are
regulated by the HR pathway. These genes can be sys-
tematically identified by using RNAi to knockdown the
key genes in this pathway. Peng et al. [27] utilized
MCF-10A immortalized mammary epithelial cells to
build a gene signature composed of the differentially
expressed genes common among three different single-
gene (BRCA1, RAD51, and BRIT1) knockdown experi-
ments. This signature was used in breast tumor samples
to predict patients with HR defects and their overall
clinical outcome. However, their signature contained
just a small set of the most differentially expressed
genes, rather than fully utilizing the knockdown pro-
files, potentially introducing bias.
In this study, we proposed a novel computational
framework to investigate the similarity between the
gene expression profiles derived from RNAi experi-
ments and breast tumors gene expression profiles. In
particular, we used the complete knockdown profiles
generated by Peng et al. [27] to infer whether the gene
expression of breast tumors from six different breast
cancer datasets are similar with the knockdown pro-
files. These profiles contained information about every
gene that is directly or indirectly regulated by the HR
pathway when BRCA1 or RAD51 is knocked down. In
contrast to the signature-based method [27], using the
complete knockdown profile ensures a higher sensitiv-
ity. We described the utility of integrating knockdown
gene expression profiles with a rank-based algorithm
called BASE [28] and demonstrated its ability to esti-
mate similarity between an individual patient’s baseline
gene expression profile and the knockdown profile. Our
results indicated that patients stratified by knockdown
profiles have significant differences in terms of their
breast cancer classification, prognosis, genome instabil-
ity, and neoadjuvant chemosensitivity.
Methods
Datasets
The gene expression data for BRCA1 and RAD51 knock-
down were generated by Peng et al. [27] and downloaded
from the Gene Expression Omnibus (GEO) database [29]
with accession ID GSE54266. The data contained gene ex-
pression profiles for MCF-10A that were transfected by
shRNA control or shRNA designed to knockdown BRCA1
or RAD51. Expression profiles replicated were averaged to
obtain three profiles for control, BRCA1 knockdown, and
RAD51 knockdown, respectively.
A total of six breast cancer datasets were used in this
study as summarized in Additional file 1: Table S1. The
Larsen dataset (GSE40115) contains gene expression
profiles for 275 breast cancer samples, including 128
from sporadic cases, as well as 33 with BRCA1 and 22
with BRCA2 germ-line mutations [30]. The METABRIC
dataset was downloaded from the European Genome
Phenome Archive with accession ID EGAS00000000083,
containing profiles for 144 normal breast and 1992 tumor
samples [31]. The Ur-Rehman dataset (GSE47561) is
metadata that combined samples with 10 datasets, in
which 1170 samples with known relapse-free survival
were used in our analysis [32]. The Vijver dataset was
downloaded from the Netherlands Cancer Institute
(http://ccb.nki.nl/data/) [33], containing 295 breast can-
cer samples. The Hatzis dataset (GSE25066) contains
gene expression profiles for 508 HER2-negative invasive
breast tumor samples that were collected by fine needle
aspiration (FNA) or core biopsy (CBX) prior to any sys-
temic therapy. Patients were then treated by neoadju-
vant taxane-anthracycline chemotherapy and followed
to assess the treatment efficacy (pathological complete
response or residual disease) [34]. The TCGA breast
cancer dataset was downloaded from TCGA Data Portal
website (http://tcga-data.nci.nih.gov/tcga/) [35]. The genes
included in these six breast cancer datasets showed high
consistency (Additional file 1: Figure S1).
Calculation of RIPS
The knockdown profiles manifested downstream genes
that were directly or indirectly regulated by the HR
pathway when knocking down BRCA1 or RAD51. By in-
tegrating the knockdown and baseline tumor expression
profiles, we developed a novel computational method to
examine the similarity between the baseline expression
levels of HR pathway regulated genes and tumor. The
calculation was performed as the following steps.
In the first step, we compared the expression levels of
all genes in BRCA1/RAD51 knockdown versus control
to obtain a vector f = {f1, f2, …, fn}, where n was the
total number of genes and fi was the log ratio expres-
sion of gene i in BRCA1/RAD51 knockdown versus
control. Following that, we standardized the vector f by
subtracting the mean and then divided by the standard
deviation of log ratios, resulting in a vector of z-scores,
z = {z1, z2, …, zn}. We then split the z vector into two
vectors z+ and z–. In z+, all positive values (upregulated
genes) were preserved while negative values (downreg-
ulated genes) were replaced by 0. Similarly, in z–, all
negative values were preserved while positive values
were replaced by 0. Each zi corresponded to a p value (pi)
referring to the standard normal distribution. Finally, we
obtained two weight vectors w+ and w–, in which wi was
calculated as –log10(pi) followed by trimming (to avoid
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extreme values, we used 10 as a cutoff to trim the –
log10(pi)) and rescaling so that wi takes a value within
[0, 1]. The vectors w+ and w– assigned weights to up-
regulated and downregulated genes by the BRCA1/
RAD51 knockdown event. In w+, a higher value (i.e.
close to 1) indicated higher upregulation and w+i = 0 for
all downregulated genes. Conversely, in w– a higher
value indicates higher downregulation and w-i = 0 for all
upregulated genes.
In the second step, we processed breast cancer gene ex-
pression data to obtain relative expression levels of genes
in each sample. Gene expression data measured by one-
channel array platforms represent absolute expression
level of genes. We transformed the values into log scale
and then performed quantile normalization [36] at the
gene level so that all samples in a dataset have a matching
distribution. Then for each gene, we converted its values
into relative expression levels by subtracting its median
expression over all samples. For gene expression data
measured by two-channel array platforms, no processing
was required, since gene expression levels were already
represented as relative values (log ratios). Eventually, we
obtained a gene expression matrix that contained relative
expression levels of all genes in all samples.
In the third step, given the gene expression profile for
a breast cancer sample (e = {e1, e2,…, en}) and the two








n}), we applied a modified version of a statis-
tical method called BASE [28] to calculate the similarity
score in this sample. Briefly, genes in e, w+, and w– were
reordered so that the relative expression of genes de-
creased monotonically. Then two CDF (cumulative dis-
tribution function) -like functions, denoted as h(i) and
b(i), were defined to quantify the correlation between
vector e and vector w (w+ or w–). When highly expressed
genes tend to have higher weight in vector w, h(i) in-
creases rapidly and b(i) increases slowly. The opposite
will be observed if highly expressed genes tend to have
lower weight in vector w. Thus, the maximum deviation
between h(i) and b(i) could be used to represent the
biased distribution of HR-regulated genes (genes with
high weight) in the expression profile for a sample. After
normalizing the resulting maximum deviation against an
empirical null distribution generated by permutations,
we obtained two scores, score+ and score–, based on w+,
and w–, respectively.
Finally, we combined the two scores to obtain a simi-
larity score = score+ – score–. The resulting scores
measure the similarity between the expression profiles
of these tumor samples with the knockdown profile for
BRCA1 or RAD51. The higher the scores, the more
similar a tumor’s baseline expression is to the expres-
sion of knockdown BRCA1 or RAD51. Furthermore, we
found that the calculated similarity score reflects the
ability of cell proliferation (see “Results” for details).
Therefore, we took the negative of the similarity score cal-
culated by our method, and defined it as the RNA-
Interference derived Proliferation Score (RIPS), where a
low RIPS indicates high similarly to cell cycle arrest caus-
ing by the knockdown profile and thus low cellular
proliferation.
Survival analysis
The Cox proportional hazards model, Wald test, was
used to investigate the relationships between the RIPS
and patient survival while considering important clinical
factors such as age and tumor stage. To compare survival
times of patients in different groups, the Kaplan–Meier
method, log-rank test, was used to estimate the survival
functions of each group. The R package “survival” was
used to implement survival analysis.
Random forest model to predict pathologic complete
response versus residual disease classes
Random forest models [37] were used to predict the
classes, pathologic complete response (pCR) versus re-
sidual disease (RD), in the Hatzis dataset. In one model,
only clinical factors were used as predictors, including
age, ER status, PR status, HER2 status, stage, grade, and
node status. In another model, RIPSs for sample were
included as an additional predictor together with clinical
factors. Prediction accuracy of models was measured by
AUC scores and evaluated by using tenfold cross-
validation. For each model, evaluation was performed ten
times and the average AUC score was used to represent
the accuracy. The R package “RandomForest” was used to
implement these models.
Measurement of TCGA genome instability
Three metrics were used to measure the genome stabil-
ity of breast cancer samples from TCGA [35]. First, the
total number of somatic mutated genes in samples was
determined based on DNA-sequencing data. A Muta-
tion Annotation File was downloaded from the Broad
Institute’s GDAC Firehose Pipeline [38]. We summed
and recorded the number of genes that had at least one
non-synonymous or indel mutation for each patient,
representing an absolute count of somatic mutations
within that tumor. Second, copy number deviation
(CND) was calculated based on copy number variation
data of samples by using the following equation:
CND ¼
Xk




where ci and fi were the copy number and the size of
DNA segment i, k was the total number of abnormal
segments called by TCGA, and N is the size of human
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genome. This value measured the deviation of a cancer
genome from normal in terms of copy number, with a
value of 0 indicated a completely normal genome. A
high CND indicated more deletions or duplications for
regions of the genome. Copy number variation segment
files for breast cancer samples were downloaded from
TCGA portal [35]. Finally, we utilized data containing an
estimate of the “ploidy” for each TCGA sample (which
were calculated using the ABSOLUTE algorithm [39])
and downloaded this file from [40].
Gene functional annotation analysis
Gene functional annotation analysis was performed to
identify pathways that were enriched in the upregulated
and downregulated genes by BRCA1 or RAD51 knock-
down. Upregulated and downregulated genes were identi-
fied as the 300 most increased or decreased expression
genes, respectively, in the BRCA1/RAD51 knockdown
with respect to the control expression profile in the
GSE54266 dataset [29]. The web-based DAVID functional
annotation tool (http://david.abcc.ncifcrf.gov/) was used to
perform pathway enrichment analyses.
Results
Overview of analyses in this study
Our computational framework began by calculating
RIPS between either BRCA1 or RAD51 knockdown
profiles and the expression profiles of individual breast
tumors as shown in Fig. 1. To carry out computation of
RIPS, we used the BASE algorithm [28], which integrates
gene knockdown profiles with tumor gene expression pro-
files. The calculated RIPS was then correlated with differ-
ent genomic and pathological characteristics. First, by
applying the RIPSs, we were able to discriminate with
fairly high accuracy breast tumors containing germline
BRCA1 or BRCA2 mutations from those that occurred
sporadically. Second, we showed that RIPS is highly pre-
dictive of prognosis among breast cancer patients. Third,
we demonstrated that treatment efficacy of neoadjuvant
chemotherapy can be accurately predicted using RIPS.
Finally, we estimated the genomic instability and DNA
Fig. 1 Overview of computational analysis in this study. Briefly, we utilize knockdown experiments of BRCA1 or RAD51 in combination with breast
cancer patient gene expression data to estimate the similarity score between the knockdown profiles and tumor expression profiles. The score
can be used to predict sporadic cancers from hereditary cancers, predict patient survival outcome, predict chemosensitivity, and correlate with
genome instability
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methylation levels of breast cancer samples using RIPS as
predictor.
Comparison between hereditary and sporadic breast
cancer samples
We first examined the functional categories of genes
regulated by BRCA1 or RAD51 identified from their
knockdown profiles. As a result, we identified 545
upregulated and 651 downregulated genes resulting
from BRCA1 knockdown and 643 upregulated and 740
downregulated genes resulting from RAD51 knockdown
(Additional file 1: Table S2). The pathway enrichment
results showed that the genes downregulated by BRCA1
or RAD51 are highly enriched in DNA replication, cell
cycle, and mismatch repair pathways (Additional file 1:
Table S3). This suggested that knockdown of BRCA1 or
RAD51 affects cell proliferation, consistent with their
functions in protecting the genome from double-strand
DNA breaks during DNA replication [4, 41].
To further test the interpretation of knocking down
BRCA1 and RAD51, we then applied our method to cal-
culate the similarity scores using gene expression data
published by Larsen et al., which contains 33 germ-line
BRCA1 mutations, 22 germ-line BRCA2 mutations, and
128 non-familial sporadic cancers [30]. The resulting
similarity scores measured the similarity between the ex-
pression profiles of these tumor samples with the knock-
down profiles. The higher the similarity score, the more
similar a tumor’s baseline expression is to the expression
of knockdown profile. Interestingly, we observed lower
scores for hereditary samples compared with sporadic
ones, although hereditary samples carry BRCA1/2
mutations and are associated with defective HR pathway.
Further analyses indicated these similarity scores were
negatively correlated with the expression of MKI67, a
well-known proliferation marker [42] (R = –0.81 and
R = –0.78 for BRCA1 and RAD51, respectively). This
result indicates that the knockdown profiles of BRCA1
and RAD51 recapitulate the slowed proliferation charac-
teristic of RNAi treated cells which is consistent with the
pathway enrichment results (Additional file 1: Table S3).
Therefore, we took the negative of the calculated similarity
score and defined it as RIPS. A low RIPS indicates high
similarity to the knockdown profile inferring to the low
cellular proliferation.
Next, we calculated RIPS for individual tumors in the
Larsen et al. [30] dataset using the knockdown profile cor-
responding to either BRCA1 (Fig. 2a) or RAD51 (Fig. 2b).
In both cases, the sporadic group had significantly
lower RIPSs than both the inherited BRCA1-mutant
and BRCA2-mutant groups (p = 8e-10 versus RIPSBRCA1
and p = 8e-11 versus RIPSRAD51 by Mann–Whitney U-
test) and the combined BRCA1/BRCA2 group (Additional
file 1: Figure S2). This might be due to the defective
germline BRCA1 or BRCA2 causing more mutations
resulting in higher cell proliferation. In addition, we
noted that based on both RIPSBRCA1 and RIPSRAD51,
patients with BRCA1-mutant had higher cell prolifera-
tion which might due to stronger mutation effects of
BRCA1 compared with BRCA2 [43].
Since we observed significant differences in RIPS
distribution between sporadic and inherited cancers
(Fig. 2a and b), we postulated that RIPS could classify
tumors as either sporadic breast cancers or cancers
with germline mutations. Thus, we evaluated the sensi-
tivity and specificity of the classification by generating a
receiver operating characteristic (ROC) curve when
using RIPSBRCA1 (Fig. 2c) and RIPSRAD51 (Fig. 2d) as
separate features. RIPSRAD51 was more accurate in pre-
dicting sporadic cancers from familial cancers with an
area under the curve (AUC) of 0.778, compared to an
AUC of 0.766 yielded by RIPSBRCA1.
These observations indicate that RIPS is able to effect-
ively distinguish sporadic breast cancers from inherited
ones. In addition, the RIPSRAD51 not only had a higher
AUC but also better distinguished between sporadic ver-
sus inherited (Fig. 2a and b), which led us to conclude
that RIPSRAD51 is a more sensitive measure of the level
of cell proliferation in a breast tumor.
RIPS is prognostic in breast cancer
As cellular proliferation is highly important in breast
cancer development and progression, we tested whether
RIPS is prognostic in breast cancer patients. We applied
our method to the METABRIC dataset generated by
Curtis et al. [31], which represents the most comprehen-
sive breast cancer dataset to date containing gene ex-
pression profiles for 144 normal breast samples and
1992 primary breast tumor samples with detailed clinical
information. For each tumor in this dataset, we calcu-
lated RIPSBRCA1 and RIPSRAD51, which were used to as-
sign tumor samples to high (RIPS > 0) or low (RIPS < 0)
RIPS groups. As shown in Fig. 3a and b, both the
BRCA1-based and RAD51-based stratifications resulted
in groups with significantly different relapse-free survival
(RFS) times. Patients inferred to have a lower cell prolif-
eration demonstrated a more favorable prognosis than
those with higher inferred proliferation. Again, RFS sur-
vival analysis suggests that RIPSRAD51 is superior to
RIPSBRCA1 for inferring cell proliferation of tumor. Based
on the above results, and for simplification, we used
RIPSRAD51 alone for subsequent analyses.
With the RIPSRAD51 profile, we then investigated the
level of cell proliferation in breast cancer subtypes strati-
fied by molecular subtype, TP53 status, cancer stage,
cancer grade, lymph node status, and histopathological
subtype. We first examined the RIPSs in the five breast
cancer molecular subtypes: Basal-like, HER2-enriched,
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Luminal A, Luminal B, and Normal-like. As shown in
Fig. 3c, we observed a high level of cell proliferation in
the Basal and HER2-enriched subtypes, a low level of
proliferation in the Luminal A and Normal-like sub-
types, and an intermediate level of proliferation in the
Luminal B subtype (Mann–Whitney U-test, p = 2e-308).
This indicates that Luminal A and Normal-like cancer
samples have lower cell proliferation than the other
three subtypes.
In the METABRIC dataset, TP53 status was available
for 820 tumors, of which 99 harbored TP53 missense or
truncating mutations. Breast tumors with TP53 muta-
tions had higher RIPS compared to wild-type samples
(Mann–Whitney U-test, p = 6e-11; Fig. 3d). In addition,
we observed in the METABRIC dataset that the fre-
quency of TP53 mutations increased as RIPS increased
(Additional file 1: Figure S3A). Specifically, only 25 out
of 478 samples in the RIPS-negative (RIPS < 0) group
carried TP53 mutations compared to 74 out of the 342
RIPS-positve (RIPS > 0) group, yielding a 4.1-fold differ-
ence in TP53 mutation frequency (p = 3e-12, Chi-square
test). Similar results were also observed in the TCGA
breast cancer dataset [35] (Additional file 1: Figure S3B).
In addition, we compared RIPS of samples from normal
breasts (144 samples) with breast tumors at stages 1, 2, or
3 (stage 4 samples were excluded due to limited number).
RIPS was relatively low in normal breast samples and
increased dramatically with increasing tumor stage
(Mann–Whitney U-test, p = 8e-91; Fig. 3e). Similarly, RIPS
increased significantly with increasing tumor grade
(Mann–Whitney U-test, p = 1e-113; Fig. 3f) and the num-
ber of lymph nodes (Mann–Whitney U-test, p = 2e-08;
Fig. 3g). Here, lymph node status was determined by lymph
node count: L0 (no positive nodes), L1 (1–3 positive nodes),
L2 (4–9 positive nodes), and L3 (>10 nodes) [44].
Moreover, our results indicated that ER+ tumors had
lower RIPS than ER– and triple-negative (TNBC) tu-
mors (Mann–Whitney U-test, p = 2e-122; Fig. 3h). As a
consequence, we examined the prognostic predictive
power of RIPS in patients with ER+ and ER– tumors
separately. We found that RIPS predicted RFS in ER+
samples (p = 2e-11, Fig. 3i), but was nearly not as effect-
ive in ER– samples (p = 0.2, Fig. 3j). We postulate that
this discrepancy was because of the larger distribution of
RIPSs in ER+ tumors, whereas ER– tumors have a
smaller dynamic range of RIPSs (Fig. 3h).
Fig. 2 Inherited and sporadic breast cancer samples are distinguished by RIPS. a Boxplot of BRCA1-inherited, BRCA2-inherited cancers, and non-
familial sporadic cancer patient RIPS scores (BRCA1 based; RIPS BRCA1). The width of each box is proportional to the sample number. The p value is
a calculation of one-way analysis of variance (ANOVA). b Same as (a) but utilizing RIPS RAD51. c A ROC curve from predicting sporadic cancers from
inherited cancers using only RIPS BRCA1. d Same as (c) but using RIPS RAD51
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To examine whether RIPS contributes additional prog-
nostic information not explained by conventional clinical
factors, we constructed a multivariate Cox regression
model that included both RIPS as well as other import-
ant clinical factors (e.g. age, tumor size, ER status, HER2
status, lymph node, stage, and grade) as covariates. This
result indicates that the RIPS provides significant add-
itional information about patient prognosis (p = 9.8e-05)
even after considering all these clinical factors (Table 1).
We further validated the predictive value of RIPSRAD51
with two additional breast cancer datasets. We calculated
tumor RIPS in the Ur-Rehman dataset that combines
Fig. 3 Analyses of METABRIC breast cancer patients using RIPS. a Kaplan–Meier plot using RIPS BRCA1. Patients with low cell proliferation (RIPS < 0;
green curve) have a higher survival likelihood than patients with high cell proliferation (RIPS > 0; red curve). b Kaplan–Meier plot using RIPSRAD51.
c Boxplot of RIPSRAD51 comparing samples across molecular subtypes. The width of each box is proportional to the sample number. The p value is a
calculation of one-way analysis of variance (ANOVA). d Boxplot of RIPSRAD51 comparing p53 mutant to WT-p53 samples. e Boxplot of RIPSRAD51
comparing samples across tumor stages. f Boxplot of RIPSRAD51 comparing samples across lymph nodes status. g Boxplot of RIPSRAD51 comparing
samples across tumor grades. h Boxplot of RIPSRAD51 comparing ER+, ER–, and TNBC samples. i Kaplan–Meier plot using RIPSRAD51 for only ER+ patients.
j Kaplan–Meier plot using RIPSRAD51 for only ER– patients
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multiple independent datasets measured by Affymetrix
one-channel arrays [32], as well as the Vijver dataset that
was generated using only two-channel arrays [33]. In both
datasets, patients with low cell proliferation (RIPS < 0)
showed significantly better survival outcome than those
with high HR cell proliferation (RIPS > 0). Again, the
predictive power of RIPSs was greater in ER+ tumors than
ER– tumors (Fig. 4).
RIPS predicts response to neoadjuvant chemotherapy
Treatment by chemotherapeutics is broadly applied to
manage many types of cancers. To discover whether RIPS
Table 1 The result of a multivariate Cox regression model using METABRIC database
Variable Type Coefficient p value Hazard ratio 95 % CI
RIPSRAD51 Continuous 1.8E-02 9.8E-05 1.018 1.009 ~ 1.027
Age Continuous 6.0E-04 9.0E-01 1.000 0.992 ~ 1.009
Tumor size Continuous 1.2E-02 5.3E-07 1.012 1.008 ~ 1.017
ER status Binary –1.7E-01 2.1E-01 0.845 0.651 ~ 1.097
HER2 status Binary 3.9E-01 5.3E-03 1.470 1.122 ~ 1.926
Lymph node Integer 9.0E-02 1.0E-15 1.094 1.071 ~ 1.119
Stage Integer 9.2E-01 1.4E-01 0.922 0.828 ~ 1.028
Grade Integer 9.2E-01 1.8E-01 0.922 0.939 ~ 1.409
Except RIPSRAD51, other important clinical factors including age, tumor size, ER status, HER2 status, lymph node, stage, grade are also considered as variables to
input to a Cox regression model. RIPSRAD51 is significantly prognostic of survival
Fig. 4 Prognosis of Ur-Rehman and Vijver breast cancer patients using RIPSRAD51. a Kaplan–Meier plot of RIPSRAD51 in Ur-Rehman database. Patients
with higher cell proliferation (RIPS >0, red curve) shows worse survival prognosis. b Kaplan–Meier plot of RIPSRAD51 for ER+ patient samples in Ur-
Rehman data. Patients with higher cell proliferation (red curve) show worse survival prognosis. c Kaplan–Meier plot of RIPSRAD51 for ER– patient
samples in Ur-Rehman data. d Kaplan–Meier plot of RIPSRAD51 in Vijver database. Patients with higher cell proliferation (RIPS >0, red curve) shows
worse survival prognosis. e Kaplan–Meier plot of RIPSRAD51 for Vijver ER+ patient samples. Patients with higher cell proliferation (red curve) show
worse survival prognosis. f Kaplan–Meier plot of RIPSRAD51 for Vijver ER– patient samples.
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predicts the responsiveness of breast cancer patients to
neoadjuvant chemotherapy, we calculated RIPS of tumors
included in the GSE25055 discovery dataset from Hatzis
et al. [34]. This dataset contains clinical outcomes and re-
sponse data from 508 patients with breast cancer treated
with neoadjuvant chemotherapy. First, we found that RIPS
was prognostic of survival outcome; patients with RIPS-low
tumors exhibited favorable prognoses (Fig. 5a, p = 0.01).
Second, we stratified patients into three groups based on
RIPS and compared the proportions of patients that
showed pCR after administration of neoadjuvant
chemotherapy. As shown in Fig. 5b, the pCR rate was
5.8 %, 13.0 %, and 36.9 % in the low, intermediate,
and high RIPS groups, respectively. Impressively, breast
cancer samples with high RIPS were 6.4-fold more
likely to respond to neoadjuvant therapy than those
with low RIPS. This suggests that RIPS could be used
as a biomarker to predict the responsiveness of indi-
vidual breast tumors to neoadjuvant chemotherapy.
Therefore, RIPS may help oncologists, in a more per-
sonalized treatment fashion, to decide whether to use
chemotherapeutics to treat individual patients.
Furthermore, we used RIPS to classify patients into those
who achieve pCR versus those harboring RD following neo-
adjuvant chemotherapy using ROC; this yielded high accur-
acy (AUC= 0.744, Fig. 5c). Moreover, much higher
prediction accuracy was achieved in ER+ (AUC= 0.667)
than in ER– breast cancers (AUC= 0.638). We constructed
two Random Forest models to classify pCR versus RD sam-
ples in the GSE25055 dataset—in one model, we included
both RIPS and clinical factors (i.e. age, ER status, PR status,
HER2 status, stage, grade, and node status) as predictors,
while in the other model we included only clinical factors.
Cross-validation results indicated that utilizing RIPS
improved the mean accuracy to predict tumor response to
neoadjuvant chemotherapy from an AUC of 0.682 to 0.711
(Fig. 5d). We also implemented these analyses in the valid-
ation dataset (GSE25065) to ensure that our results
remained consistent (Additional file 1: Figure S4).
RIPS correlates with genomic instability in breast cancer
Next, we investigated whether the calculated RIPS is
able to infer genome instability. Specifically, we used
three different metrics of genomic instability within The
Fig. 5 Prognosis of Hatzis discovery data using RIPSRAD51. a Kaplan–Meier plot comparing survival of high to low cell proliferation patients. Patients
with low RIPS (green curve) have significantly higher survival than patients with high RIPS (red curve). b Barplot of the pCR rate within low, intermediate,
and high RIPS groups comparing the number of RD patients (gray) to the number of patients achieving pCR (white). The pCR rate is given above each
bar. c ROC curve calculating accuracy in classifying pCR patients. Black curve: All patients in Hatzis dataset (AUC= 0.744). Magenta curve: ER+ only Hatzis
patients (AUC= 0.667). Cyan curve: ER– only Hatzis patients (AUC = 0.638). d Barplot comparing average AUCs from a random forest model either including
RIPSRAD51 with clinical information or not. Mean AUC is given above each bar. Error bars represent standard deviation in the AUC distribution
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Cancer Genome Atlas (TCGA) breast cancer data [35].
First, we counted the total number of somatically mutated
genes for each sample (see “Methods”). Second, based on
copy number variation data we defined a metric termed
CND, which is a weighted average of absolute copy number
aberrations in breast cancers (see “Methods”). Finally, using
the ABSOLUTE algorithm [39], we estimated the ploidy of
each breast tumor. We then calculated the RIPS of all
TCGA breast cancers and stratified patients into three
groups based on low, intermediate, or high RIPS. We com-
pared the three groups by total number of somatically
mutated genes, CND, and ploidy. As shown in Fig. 6, these
comparisons indicated significant associations between
RIPS and these three metrics of genome instability. Each
metric showed that cancers with higher RIPS have more
unstable genomes. RIPS-high tumors retain more mutation
counts than RIPS-intermediate and RIPS-low tumors
(Fig. 6a, Mann–Whitney U-test, p = 1e-08). Similarly, RIPS-
high tumors have more CND (Fig. 6b, Mann–Whitney U-
test, p = 6e-18) and ploidy (Fig. 6c, Mann–Whitney U-test,
p = 3e-06) than the other two tumor groups.
Genomic alterations in RIPS-high breast cancers
TCGA provides diverse types of genomic data for breast
tumors, enabling investigation of specific genomic alter-
ations in samples with high cell proliferation. We first
examined somatic mutation data to identify genes with a
significant differential mutation frequency among low,
intermediate, and high RIPS samples. As a result, we
identified three genes using a false discovery rate
(FDR) < 0.01 threshold. The most significant gene was
TP53, which was mutated in 6.6 %, 29.1 %, and
64.3 % of tumors in the low, intermediate, and high
RIPS groups, respectively (p = 4e-32, Chi-square test).
This finding confirms our previous result that a
higher RIPSRAD51 correlates with a higher number of
TP53 mutations in both METABRIC and TCGA data-
sets (Additional file 1: Figure S3). In addition, we found
that PIK3CA and MAP3K1 showed higher mutation rates
in samples with lower RIPS (Additional file 1: Figure S5).
We then compared the mRNA expression levels of
BRCA1, BRCA2, and RAD51 in the RIPS-low, RIPS-
intermediate, and RIPS-high groups in the TCGA dataset.
Interestingly, all three genes showed elevated expression
levels in samples with the high RIPS group (Fig. 7a–c).
This indicates that higher proliferative tumor cells are
associated with higher expression levels of BRCA1,
BRCA2, and RAD51. In addition, we examined the ex-
pression levels of these three genes in hereditary can-
cers with BRCA1/BRCA2 germline mutations versus
sporadic cancers (from the Larsen et al. dataset [30]; 33
BRCA1-mutated cancers, 22 BRCA2- mutated cancers,
and 128 sporadic cancers). Compared with sporadic breast
cancers, the expression levels of BRCA2 were significantly
elevated in BRCA1-mutated samples (p = 5e-4, t-test), the
expression level of BRCA1 was significantly elevated in
BRCA2-mutated cancers (p = 9e-5, t-test), and the expres-
sion level of RAD51 was significantly elevated in both
BRCA1-mutated and BRCA2-mutated cancers (p = 5e-7
and p = 1e-4, t-test) (Additional file 1: Figure S6). This
suggests a possible negative feedback loop in the HR path-
way that cells attempt to compensate the defects in
BRCA1/2-mutanted tumors by upregulating other HR
pathway genes.
Finally, we found that the differential expression of
BRCA1, BRCA2, and RAD51 may be partially explained
by changes in promoter DNA methylation. In particular,
higher levels of DNA methylation in gene promoters
correlate with transcriptional silencing [45]. From TCGA
data, after excluding tumors with a somatic mutation in
Fig. 6 High cell proliferation correlates with high genomic instability metrics. a Boxplot of log10 transformed mutation counts in different cell
proliferation groups. Each gray spot indicates log10 transformed mutation counts. The width of each box is proportional to the sample number
and the p value represents an ANOVA calculation. b Boxplot of the CND score distributions in the three groups. c Boxplot of estimated tumor
ploidy distributions in the three groups
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BRCA1, BRCA2, or RAD51, we compared RIPS-low,
RIPS-intermediate, and RIPS-high groups in terms of
methylation levels in CpG sites near BRCA1, BRCA2, or
RAD51. Our analyses identified several CpG sites with
significant differential methylation levels. For example,
cg26458617, a CpG site located 403 bp upstream of the
transcription start site (TSS) of BRCA2, showed a much
lower methylation level in the RIPS-high group com-
pared to the RIPS-intermediate and RIPS-low groups
(Mann–Whitney U-test, p = 1e-04) (Fig. 7d). In another
similar example, cg12836863, a CpG site located 593 bp
upstream of the TSS of BRCA2, also showed lower methy-
lation levels in the RIPS-high group (Mann–Whitney U-
test, p = 1e-08) (Fig. 7e). Integrating the compensatory
mechanism proposed above (Fig. 7b and c), we found that
the methylation levels of cg26458617 and cg12836863 are
inversely correlated with the expression levels of BRCA2
in samples with high cell proliferation, respectively. This
suggests that hypo-methylation in the promoter region of
a gene is able to cause its elevated expression. Moreover,
we extended such analysis to the CpGs associated with 27
HR-related genes defined by the KEGG HR pathway [46]
and also found some interesting results (Additional file 1:
Table S4). For example, cg01605516 (correlated with the
expression level of XRCC2, which is a member of the
RAD51 family [47]), a CpG site located 3527 downstream
of the TSS, showed significantly higher methylation level
in samples with higher cell proliferation (Mann–Whitney
U-test, p = 0.001). We found that the methylation of
cg01605516 is positively correlated with XRCC2 expres-
sion in samples with high cell proliferation (Additional
file 1: Figure S7).
Discussion
In this study, we developed a new computational
method to infer the level of cell proliferation in breast
tumor samples by referring to gene expression profiles
generated by RNAi-mediated knockdown of BRCA1 or
RAD51 in MCF-10A cells. We applied our method to
multiple breast cancer datasets to demonstrate that the
Fig. 7 Difference of gene expression and DNA methylation in different RIPS groups. a BRCA1 expressions in different RIPS groups. Gray dots
indicate the amount of BRCA1 expression for a particular sample. The width of the box is proportional to the number of samples. Reported
p value is a result of ANOVA calculation. b BRCA2 expressions in different RIPS groups. c RAD51 expressions in different RIPS groups. d DNA
methylation levels of cg26458617 in different RIPS groups. Gray dots indicate levels of DNA methylation of this cpg site. The width of the
box is proportional to the number of samples. Reported p value is a result of ANOVA calculation. e DNA methylation levels of cg12836863
in different RIPS groups. f DNA methylation levels of cg01605516 in different RIPS groups
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inferred cell proliferation score can discriminate heredi-
tary from sporadic breast cancer samples, predict prog-
nosis and efficacy of neoadjuvant chemotherapy, and
correlate with genomic instability in breast cancer.
We started our analysis from the BRCA1 and RAD51
knockdown profiles provided by Peng et al. [27]. As
suggested by the pathway enrichment analysis, the
readout of knocking down either BRCA1 or RAD51
affects DNA replication more than DNA repair (Additional
file 1: Table S3). Moreover, the RIPSs inferred by using
BRCA1/RAD51 knockdown profile were positively corre-
lated with the expression of MKI67, a well-known prolifera-
tion marker [42] (R = 0.81 and R = 0.78 for BRCA1 and
RAD51, respectively). These results suggested that the in-
ferred RIPSs are more likely to reflect the effect of BRCA1
or RAD51 knockdown on reducing cell proliferation. This
is consistent with previous studies that HR deficiency re-
sults in more DNA damage which delays the activation of
cell cycle checkpoints and causes cell cycle arrest [4, 41].
Then, we calculated two RIPS measures using either
the BRCA1 or RAD51 knockdown profile as a reference;
however, our analyses indicated that the RAD51 knock-
down provided a better estimator of the alterations of
the defective HR pathway. Compared to BRCA1, the
RAD51 knockdown profile not only yielded better results
when predicting the prognosis of breast cancer patients
and classifying BRCA mutation progeny from sporadic
cancers, but was also more highly associated with DNA
replication pathways as shown by gene functional anno-
tation enrichment analysis. Besides BRCA1 and RAD51,
Peng et al. [27] provided the knockdown profile of
BRIT1 (GSE54269), a key gene involved in HR pathway
[48], which was used to define the gene signature they
used. Additionally, we repeated the survival analysis in
the METABRIC dataset [31] using the BRIT1 knock-
down profiles (Additional file 1: Figure S8). In light of
these results, the RAD51 knockdown remained a better
estimator of the readout of HR pathway.
We found that breast tumors with inherited BRCA1 or
BRCA2 mutations tend to have higher RIPSs than spor-
adic breast tumors. Indeed, we could use RIPS to classify
hereditary versus sporadic breast tumors (Fig. 2), which
implied that RIPS is a robust biomarker in breast cancer.
In addition, RIPS provided a computational approach to
discriminate hereditary from sporadic breast tumors. We
reasoned that this was possibly due to the fact that mu-
tant BRCA1/2 carriers exhibit dysfunctional HR pathway
at the onset of carcinogenesis, whereas sporadic cancers
may have somatic mutations to develop cancer. How-
ever, we noted that discrimination was imperfect; a large
number of sporadic breast tumors were associated with
equal or higher RIPS than breast tumors from mutant
BRCA1/2 carriers. This is consistent with the concept
of BRCAness: that there exist other mechanisms that
can inactivate the HR-mediated DNA repair pathway in
sporadic breast cancer resulting in accelerating tumor
proliferation. For example, it has been shown that
BRCA1 transcription can be repressed by aberrant
methylation in its promoter in sporadic breast cancer
[17]. Thus, it would be useful to investigate the spor-
adic breast tumors with extremely low RIPS for the
identification of alternate mechanisms leading to low
cell proliferation.
Additionally, we found that patients with higher RIPS
tended to have shorter RFS intervals, but were more
likely to respond to neoadjuvant chemotherapy. This is
consistent with the fact that high cell proliferation corre-
lates with increased sensitivity to taxane chemotherapy
during inhibition of microtubule disassembly [49–51]. In
addition, we observed that breast tumors with high RIPS
were more likely to have TP53 mutations, which renders
chemotherapy less effective [52]. Thus, a combination of
RIPS with TP53 mutation status might improve the pre-
diction of response to neoadjuvant chemotherapy; tumors
with high RIPS and wild-type TP53 would be likely to be
more chemosensitive.
Moreover, we tested whether using the gene expres-
sion level of one gene or a small group of genes would
have a similar predictive and prognostic power when
compared with the complete knockdown profiles of
RAD51. We performed these analyses in the METABRIC
breast cancer dataset [31]. First, we tested the association
of gene expression of 27 genes in the KEGG HR pathway
[46] using a Cox regression model. We found that 11
genes were correlated with patient survival (FDR < 0.01),
including BLM, RAD54L, POLD1, RAD54B, EME1,
XRCC3, RPA2, POLD3, TOP3B, RAD51, and MUS81.
These results underperformed compared to using
complete knockdown profiles of RAD51 (Additional file 1:
Table S5). In addition, we performed the same analysis
using the MKI67 expression. The result suggested that
though MKI67 has been used as a biomarker for prolifera-
tion [42], its performance (p = 2e-15, survival difference p
value) was less predictive than that using the complete
profile of RAD51 (p = 1e-18, survival difference p value).
Moreover, we found that the inferred RIPS (AUC= 0.744)
is much more predictive to the response of neoadjuvant
therapy (pCR versus RD) than MKI67 (AUC= 0.668).
These results suggested that using a gene set as the
marker is more stable, which generates higher prediction.
We further identified the 300 most upregulated and
downregulated genes of RAD51 to repeat the survival ana-
lyses. The survival analysis results from using the 300
most downregulated genes as references (p = 2e-16, Wald
test) were similar to but slightly lower compared to using
the complete profile of RAD51 (p = 1e-18, Wald test). Fur-
thermore, using the 300 most upregulated genes resulted
in a much lower association with survival (p = 9e-06, Wald
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test). These suggests that the 300 most downregulated
genes better reflected the actual alterations that occur
when knocking down RAD51. Moreover, these observa-
tions demonstrate that using the complete knockdown
profile is more sensitive when capturing the alterations of
the pathway as it becomes ablated.
Recently, single-sample GSEA (ssGSEA) analysis has
been widely used to infer the activity of pre-defined path-
ways in biological samples with gene expression profiles
[53, 54]. However, in most cases, genes in a pathway were
provided as a gene set and generally without knowing
whether a gene imposes a positive or negative effect on
the pathway. Furthermore, these gene sets only indicate
which genes are part of the pathway without considering
the magnitude of its effect. BASE [28] differs in this aspect
by utilizing continuous information directly from the gene
expression profile to assess the weight of each gene. In
fact, we applied ssGSEA analysis to calculate the activities
of several curated DNA repair or damage response path-
ways in breast cancer data and failed to obtain biologically
meaningful results. The method we proposed in this study
was special in that it calculated the tumor cell prolifera-
tion by referring to knockdown profile of genes in the HR
pathway using quantitative manner, manifested from both
directly and indirectly regulated genes by the pathway,
and informs upregulation and downregulation. Thus, the
RIPS calculated by this method can effectively reflect the
readout caused by HR deficiency and can be applied as a
useful biomarker for breast cancer clinical applications.
Conclusions
Based on BRCA1 and RAD51 knockdown expression
profiles and primary breast tumor expression data, we
provide a computational method to infer the cell prolif-
eration level for each breast cancer patient. The calcu-
lated RIPS is able to accurately reflect the cell
proliferation and imply great potential in breast cancer
clinical applications.
Additional file
Additional file 1: Figure S1. The gene consistency across six different
breast cancer datasets. Figure S2. Distinguishing hereditary and
sporadic breast cancer samples using RIPS. Figure S3. TP53 mutation
rate in different breast cancer datasets. Figure S4. Prognosis of the
Hatzis validation dataset using RIPSRAD51. Figure S5. Mutation rate
of significant genes in different cell proliferation patient groups.
Figure S6. Gene expression of BRCA1, BRCA2, and RAD51 in different
breast cancer mutations. Figure S7. Gene expression of XRCC2 in
different cell proliferation patient groups. Figure S8. Prediction of
BRIT1 in the METABRIC breast cancer dataset. Table S1. Breast cancer
datasets used in this analysis. Table S2. Regulated gene lists for BRCA1
and RAD51. Table S3. Pathway enrichment of genes regulated by
BRCA1 and RAD51. Table S4. HR-related genes and their DNA methylation
level in RIPS-low, RIPS-intermediate, and RIPS-high groups. Table S5.
Survival analysis results for 11 significant HR genes using their expression
level. (PDF 843 kb)
Abbreviations
AUC: Area under the curve; CDF: Cumulative distribution function;
CND: Copy number deviation; GEO: Gene Expression Omnibus;
HR: Homologous recombination; pCR: Pathologic complete response;
RAS: Regulatory Activity Score; RD: Residual disease; RFS: Relapse-free survival;
RIPS: RNA Interference derived Proliferation Score; RNAi: RNA interference;
ROC: Receiver operating characteristic; ssGSEA: single-sample GSEA;
TCGA: The Cancer Genome Atlas; TNBC: Triple-negative breast cancer
Acknowledgements
We thank Drs. Guang Peng and Shiaw-Yih Lin for providing us with the
updated gene expression data for BRCA1 and RAD51 knockdown.
Funding
This work was supported by the American Cancer Society Research Grant
IRG-82-003-30 (to CC) and RSG-13-292-01-TBE (to TWM), Susan G. Komen
grant CCR15330848 (to TWM), the NIH Centers of Biomedical Research
Excellence (COBRE) grant GM103534 (to CC) and the Dartmouth Clinical
and Translational Science Institute, under award number UL1TR001086 (to CC)
and KL2TR001088 (to CC) from the National Center for Advancing Translational
Sciences, and Dartmouth College Norris Cotton Cancer Center Support Grant
P30CA023108 (to CC).
Availability of data and materials
The BRCA1 and RAD51 knockdown expression profiles can be downloaded
from GEO with the accession ID GSE54266. The Larsen breast cancer dataset,
Ur-Rehman breast cancer dataset, and Hatzis breast cancer dataset can
be downloaded from GEO with the accession IDs GSE40115, GSE47561,
and GSE25066 separately. The METABRIC breast cancer dataset can be
downloaded from the European Genome Phenome Archive with accession
number EGAS00000000083. The Vijver breast cancer dataset can be
downloaded from the Netherlands Cancer Institute, http://ccb.nki.nl/data/. The
TCGA breast cancer dataset can be downloaded from the TCGA Data Portal
website, http://tcga-data.nci.nih.gov/tcga/. The Mutation Annotation File
can be downloaded from the Broad Institute’s GDAC Firehose Pipeline,




Study design: CC, TX, and CW. Data collection: AK and WX. Data analysis: YW,
KM, and CC. Writing manuscript: YW, KM, MU, and TM. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1School of Electronic Information and Communications, Huazhong University
of Science and Technology, Wuhan, Hubei 430074, China. 2Department of
Molecular and Systems Biology, Geisel School of Medicine at Dartmouth,
Hanover, NH 03755, USA. 3Norris Cotton Cancer Center, Geisel School of
Medicine at Dartmouth, Lebanon, NH 03766, USA. 4Department of
Biochemistry, Geisel School of Medicine at Dartmouth, Hanover, NH 03755,
USA. 5Department of Biomedical Data Sciences, Geisel School of Medicine at
Dartmouth, Lebanon, NH 03766, USA.
Received: 13 May 2016 Accepted: 10 October 2016
References
1. Li X, Heyer WD. Homologous recombination in DNA repair and DNA
damage tolerance. Cell Res. 2008;18:99–113.
Wang et al. Genome Medicine  (2016) 8:114 Page 13 of 15
2. Lin Z, Kong H, Nei M, Ma H. Origins and evolution of the recA/RAD51 gene
family: evidence for ancient gene duplication and endosymbiotic gene
transfer. Proc Natl Acad Sci U S A. 2006;103:10328–33.
3. Duncan JA, Reeves JR, Cooke TG. BRCA1 and BRCA2 proteins: roles in health
and disease. Mol Pathol. 1998;51:237–47.
4. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common
pathway of genome protection. Nat Rev Cancer. 2012;12:68–78.
5. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair,
transcription, and cell cycle in response to DNA damage. Cancer Sci.
2004;95:866–71.
6. Cousineau I, Abaji C, Belmaaza A. BRCA1 regulates RAD51 function in
response to DNA damage and suppresses spontaneous sister chromatid
replication slippage: implications for sister chromatid cohesion, genome
stability, and carcinogenesis. Cancer Res. 2005;65:11384–91.
7. Pellegrini L, Yu DS, Lo T, Anand S, Lee M, Blundell TL, et al. Insights into
DNA recombination from the structure of a RAD51-BRCA2 complex. Nature.
2002;420:287–93.
8. Shinohara A, Ogawa H, Ogawa T. Rad51 protein involved in repair and
recombination in S. cerevisiae is a RecA-like protein. Cell. 1992;69:457–70.
9. Kawabata M, Kawabata T, Nishibori M. Role of recA/RAD51 family proteins in
mammals. Acta Med Okayama. 2005;59:1–9.
10. Helleday T. Homologous recombination in cancer development, treatment
and development of drug resistance. Carcinogenesis. 2010;31:955–60.
11. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC.
Linkage of early-onset familial breast cancer to chromosome 17q21.
Science. 1990;250:1684–9.
12. King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast
and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Science. 2003;302:643–6.
13. Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers.
Nat Rev Cancer. 2004;4:814–9.
14. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin
Oncol. 2007;25:1329–33.
15. De Summa S, Pinto R, Sambiasi D, Petriella D, Paradiso V, Paradiso A,
Tommasi S. BRCAness: a deeper insight into basal-like breast tumors. Ann
Oncol. 2013;24 Suppl 8:viii13–21.
16. Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW. Methylation of the
BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical
breast cancer specimens. Carcinogenesis. 2000;21:1761–5.
17. Catteau A, Harris WH, Xu CF, Solomon E. Methylation of the BRCA1
promoter region in sporadic breast and ovarian cancer: correlation with
disease characteristics. Oncogene. 1999;18:1957–65.
18. Deng CX, Wang RH. Roles of BRCA1 in DNA damage repair: a link between
development and cancer. Hum Mol Genet. 2003;12(Spec No 1):R113–123.
19. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C,
Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, et al. Secondary
mutations as a mechanism of cisplatin resistance in BRCA2-mutated
cancers. Nature. 2008;451:1116–20.
20. Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;16:110–20.
21. Lee E, Chuang HY, Kim JW, Ideker T, Lee D. Inferring pathway activity
toward precise disease classification. PLoS Comput Biol. 2008;4:e1000217.
22. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D,
Lancaster JM, Berchuck A, et al. Oncogenic pathway signatures in human
cancers as a guide to targeted therapies. Nature. 2006;439:353–7.
23. Tomfohr J, Lu J, Kepler TB. Pathway level analysis of gene expression using
singular value decomposition. BMC Bioinf. 2005;6:225.
24. Joosse SA, van Beers EH, Tielen IH, Horlings H, Peterse JL, Hoogerbrugge N,
Ligtenberg MJ, Wessels LF, Axwijk P, Verhoef S, et al. Prediction of BRCA1-
association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
Breast Cancer Res Treat. 2009;116:479–89.
25. Lips EH, Laddach N, Savola SP, Vollebergh MA, Oonk AM, Imholz AL,
Wessels LF, Wesseling J, Nederlof PM, Rodenhuis S. Quantitative copy
number analysis by Multiplex Ligation-dependent Probe Amplification
(MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.
Breast Cancer Res. 2011;13:R107.
26. Guo Z, Zhang T, Li X, Wang Q, Xu J, Yu H, Zhu J, Wang H, Wang C, Topol EJ,
et al. Towards precise classification of cancers based on robust gene
functional expression profiles. BMC Bioinf. 2005;6:58.
27. Peng G, Chun-Jen Lin C, Mo W, Dai H, Park YY, Kim SM, Peng Y, Mo Q,
Siwko S, Hu R, et al. Genome-wide transcriptome profiling of homologous
recombination DNA repair. Nat Commun. 2014;5:3361.
28. Cheng C, Yan X, Sun F, Li LM. Inferring activity changes of transcription
factors by binding association with sorted expression profiles. BMC Bioinf.
2007;8:452.
29. Barrett T, Edgar R. Gene expression omnibus: microarray data storage,
submission, retrieval, and analysis. Methods Enzymol. 2006;411:352–69.
30. Larsen MJ, Kruse TA, Tan Q, Laenkholm AV, Bak M, Lykkesfeldt AE,
Sorensen KP, Hansen TV, Ejlertsen B, Gerdes AM, Thomassen M.
Classifications within molecular subtypes enables identification of
BRCA1/BRCA2 mutation carriers by RNA tumor profiling. PLoS One.
2013;8:e64268.
31. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D,
Lynch AG, Samarajiwa S, Yuan Y, et al. The genomic and transcriptomic
architecture of 2,000 breast tumours reveals novel subgroups. Nature.
2012;486:346–52.
32. Ur-Rehman S, Gao Q, Mitsopoulos C, Zvelebil M. ROCK: a resource for
integrative breast cancer data analysis. Breast Cancer Res Treat.
2013;139:907–21.
33. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW,
Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al. A gene-expression
signature as a predictor of survival in breast cancer. N Engl J Med.
2002;347:1999–2009.
34. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T,
Holmes F, Souchon E, Wang H, et al. A genomic predictor of response and
survival following taxane-anthracycline chemotherapy for invasive breast
cancer. JAMA. 2011;305:1873–81.
35. Cancer Genome Atlas Network. Comprehensive molecular portraits of
human breast tumours. Nature. 2012;490:61–70.
36. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization
methods for high density oligonucleotide array data based on variance and
bias. Bioinformatics. 2003;19:185–93.
37. Svetnik V, Liaw A, Tong C, Culberson JC, Sheridan RP, Feuston BP. Random
forest: a classification and regression tool for compound classification and
QSAR modeling. J Chem Inf Comput Sci. 2003;43:1947–58.
38. Center BITGDA. Analysis-ready standardized TCGA data from Broad GDAC
Firehose stddata__2015_11_01 run. (Harvard BIoMa ed.; 2015.
39. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, Laird PW,
Onofrio RC, Winckler W, Weir BA, et al. Absolute quantification of somatic
DNA alterations in human cancer. Nat Biotechnol. 2012;30:413–21.
40. Schumacher S. ABSOLUTE PanCan12 (pancan12.sample_info.txt). 2013.
41. Chen F, Nastasi A, Shen Z, Brenneman M, Crissman H, Chen DJ. Cell
cycle-dependent protein expression of mammalian homologs of yeast
DNA double-strand break repair genes Rad51 and Rad52. Mutat Res.
1997;384:205–11.
42. Morris RJ, Liu Y, Marles L, Yang Z, Trempus C, Li S, Lin JS, Sawicki JA,
Cotsarelis G. Capturing and profiling adult hair follicle stem cells. Nat
Biotechnol. 2004;22:411–7.
43. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT,
Weber B, Lenoir G, Chang-Claude J, et al. Genetic heterogeneity and
penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families.
The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676–89.
44. Wang XX, Jiang YZ, Li JJ, Song CG, Shao ZM. Effect of nodal status on
clinical outcomes of triple-negative breast cancer: a population-based
study using the SEER 18 database. Oncotarget. 2016. doi:10.18632/
oncotarget.9432.
45. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract
Oncol. 2005;2 Suppl 1:S4–11.
46. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes.
Nucleic Acids Res. 2000;28:27–30.
47. Park DJ, Lesueur F, Nguyen-Dumont T, Pertesi M, Odefrey F, Hammet F,
Neuhausen SL, John EM, Andrulis IL, Terry MB, et al. Rare mutations in
XRCC2 increase the risk of breast cancer. Am J Hum Genet. 2012;90:734–9.
48. Rai R, Dai H, Multani AS, Li K, Chin K, Gray J, Lahad JP, Liang J, Mills GB,
Meric-Bernstam F, Lin SY. BRIT1 regulates early DNA damage response,
chromosomal integrity, and cancer. Cancer Cell. 2006;10:145–57.
49. Brito DA, Yang Z, Rieder CL. Microtubules do not promote mitotic slippage
when the spindle assembly checkpoint cannot be satisfied. J Cell Biol.
2008;182:623–9.
50. Bharadwaj R, Yu H. The spindle checkpoint, aneuploidy, and cancer.
Oncogene. 2004;23:2016–27.
51. Amadori D, Volpi A, Maltoni R, Nanni O, Amaducci L, Amadori A,
Giunchi DC, Vio A, Saragoni A, Silvestrini R. Cell proliferation as a
Wang et al. Genome Medicine  (2016) 8:114 Page 14 of 15
predictor of response to chemotherapy in metastatic breast cancer: a
prospective study. Breast Cancer Res Treat. 1997;43:7–14.
52. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE,
Akslen LA, Lonning PE. Specific P53 mutations are associated with de novo
resistance to doxorubicin in breast cancer patients. Nat Med. 1996;2:811–4.
53. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC,
Sandy P, Meylan E, Scholl C, et al. Systematic RNA interference reveals that
oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108–12.
54. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA,
Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set
enrichment analysis: a knowledge-based approach for interpreting genome-
wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–50.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wang et al. Genome Medicine  (2016) 8:114 Page 15 of 15
